NCT05295680View on ClinicalTrials.gov

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

PHASE2RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions

Primary Sclerosing Cholangitis

Interventions

DRUG

Hymecromone

Hymecromone 400 mg 3 times daily by mouth.

Trial Locations (2)

94063

RECRUITING

Stanford Clinic, Redwood City

94305

RECRUITING

Stanford Clinic, Stanford

All Listed Sponsors

lead

Aparna Goel

OTHER